Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms
- PMID: 22357456
- DOI: 10.1038/clpt.2011.328
Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms
Abstract
Crohn's disease and ulcerative colitis are chronic inflammatory disorders resulting from immune dysregulation. Patients who fail conventional medical therapy require biological treatment with monoclonal antibodies (mAbs). Although mAbs are highly effective for induction and maintenance of clinical remission, not all patients respond, and a high proportion of patients lose response over time. One factor associated with loss of response is immunogenicity, whereby the production of antidrug antibodies accelerates mAb clearance. However, other factors related to patient and disease characteristics also influence the pharmacokinetics of mAbs. These factors include gender, body size, concomitant use of immunosuppressive agents, disease type, serum albumin concentration, and the degree of systemic inflammation. Because it is important to maintain clinically effective concentrations to provide optimal clinical response and drug exposure is affected by patient factors, a better understanding of the pharmacology of mAbs will ultimately result in better patient care.
Similar articles
-
Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease.Clin Gastroenterol Hepatol. 2012 Oct;10(10):1079-87; quiz e85-6. doi: 10.1016/j.cgh.2012.06.032. Epub 2012 Jul 17. Clin Gastroenterol Hepatol. 2012. PMID: 22813440 Review.
-
Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.Scand J Gastroenterol. 2009;44(7):774-81. doi: 10.1080/00365520802699278. Scand J Gastroenterol. 2009. PMID: 19140087 Review.
-
[Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].Ugeskr Laeger. 2010 Jan 4;172(1):44-7. Ugeskr Laeger. 2010. PMID: 20056095 Danish.
-
State-of-the-art: Immunosuppression and biologic therapy.Dig Dis. 2010;28(3):536-42. doi: 10.1159/000320413. Epub 2010 Sep 30. Dig Dis. 2010. PMID: 20926883 Review.
-
Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.J Clin Pharmacol. 2015 Mar;55 Suppl 3:S39-50. doi: 10.1002/jcph.374. J Clin Pharmacol. 2015. PMID: 25707962 Review.
Cited by
-
Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions.Pharmaceutics. 2021 Mar 21;13(3):422. doi: 10.3390/pharmaceutics13030422. Pharmaceutics. 2021. PMID: 33800976 Free PMC article. Review.
-
Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.Medicine (Baltimore). 2015 May;94(18):e673. doi: 10.1097/MD.0000000000000673. Medicine (Baltimore). 2015. PMID: 25950682 Free PMC article.
-
AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6.Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3161-6. doi: 10.1073/pnas.1222051110. Epub 2013 Feb 4. Proc Natl Acad Sci U S A. 2013. PMID: 23382195 Free PMC article.
-
Intestinal barrier dysfunction orchestrates the onset of inflammatory host-microbiome cross-talk in a human gut inflammation-on-a-chip.Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10539-E10547. doi: 10.1073/pnas.1810819115. Epub 2018 Oct 22. Proc Natl Acad Sci U S A. 2018. PMID: 30348765 Free PMC article.
-
Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.Clin Gastroenterol Hepatol. 2021 Mar;19(3):511-518.e6. doi: 10.1016/j.cgh.2020.03.072. Epub 2020 Apr 26. Clin Gastroenterol Hepatol. 2021. PMID: 32348905 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
